发布求助
文献互助 智能选刊 最新文献

Therapeutic delivery最新文献

筛选
英文 中文
Industry Update, May 2024. 行业最新情况，2024 年 5 月。
IF 3
Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-08-08 DOI: 10.1080/20415990.2024.2383162
Elaine Harris
{"title":"Industry Update, May 2024.","authors":"Elaine Harris","doi":"10.1080/20415990.2024.2383162","DOIUrl":"10.1080/20415990.2024.2383162","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"737-742"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141902987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanotechnology-assisted combination drug delivery: a progressive approach for the treatment of acute myeloid leukemia. 纳米技术辅助联合给药：治疗急性髓性白血病的渐进方法。
IF 3
Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-09-13 DOI: 10.1080/20415990.2024.2394012
Neelam Poonia, Nikita Vijay Jadhav, Davuluri Mamatha, Manoj Garg, Atul Kabra, Amit Bhatia, Shreesh Ojha, Viney Lather, Deepti Pandita
{"title":"Nanotechnology-assisted combination drug delivery: a progressive approach for the treatment of acute myeloid leukemia.","authors":"Neelam Poonia, Nikita Vijay Jadhav, Davuluri Mamatha, Manoj Garg, Atul Kabra, Amit Bhatia, Shreesh Ojha, Viney Lather, Deepti Pandita","doi":"10.1080/20415990.2024.2394012","DOIUrl":"10.1080/20415990.2024.2394012","url":null,"abstract":"<p><p>Acute myeloid leukemia (AML), a heterogeneous hematopoietic cancer prevalent in adults, has been a leading cause of leukemia-associated deaths for decades. Despite advancements in understanding its pathology and pharmacological targets, therapeutic strategies have seen minimal change. The standard treatment, combining cytarabine and anthracycline, has persisted, accompanied by challenges such as pharmacokinetic issues and non-specific drug delivery, leading to severe side effects. Nanotechnology offers a promising solution through combination drug delivery. FDA-approved CPX351 (VYXEOS™) a liposomal formulation delivering doxorubicin and cytarabine, exemplifies enhanced therapeutic efficacy. Ongoing research explores various nanocarriers for delivering multiple bioactives, addressing drug targeting, pharmacokinetics and chemoresistance. This review highlights nanotechnology-based combination therapies for the effective management of AML, presenting a potential breakthrough in leukemia.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"893-910"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer. 将 siRNA 用于治疗乳腺癌和三阴性乳腺癌。
IF 3
Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-09-25 DOI: 10.1080/20415990.2024.2400044
Boya Manasa Sai, Yirivinti Hayagreeva Dinakar, Hitesh Kumar, Rupshee Jain, Sharyu Kesharwani, Siddharth S Kesharwani, Shyam Lal Mudavath, Ajmeer Ramkishan, Vikas Jain
{"title":"Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer.","authors":"Boya Manasa Sai, Yirivinti Hayagreeva Dinakar, Hitesh Kumar, Rupshee Jain, Sharyu Kesharwani, Siddharth S Kesharwani, Shyam Lal Mudavath, Ajmeer Ramkishan, Vikas Jain","doi":"10.1080/20415990.2024.2400044","DOIUrl":"10.1080/20415990.2024.2400044","url":null,"abstract":"<p><p>Breast cancer is the leading cause of cancer-related deaths among women globally. The difficulties with anticancer medications, such as ineffective targeting, larger doses, toxicity to healthy cells and side effects, have prompted attention to alternate approaches to address these difficulties. RNA interference by small interfering RNA (siRNA) is one such tactic. When compared with chemotherapy, siRNA has several advantages, including the ability to quickly modify and suppress the expression of the target gene and display superior efficacy and safety. However, there are known challenges and hurdles that limits their clinical translation. Decomposition by endonucleases, renal clearance, hydrophilicity, negative surface charge, short half-life and off-target effects of naked siRNA are obstacles that hinder the desired biological activity of naked siRNA. Nanoparticulate systems such as polymeric, lipid, lipid-polymeric, metallic, mesoporous silica nanoparticles and several other nanocarriers were used for effective delivery of siRNA and to knock down genes involved in breast cancer and triple-negative breast cancer. The focus of this review is to provide a comprehensive picture of various strategies utilized for delivering siRNA, such as combinatorial delivery, development of modified nanoparticles, smart nanocarriers and nanocarriers that target angiogenesis, cancer stem cells and metastasis of breast cancer.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"871-891"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11498026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted drug delivery to the thrombus by fusing streptokinase with a fibrin-binding peptide (CREKA): an in silico study. 通过融合链激酶和纤维蛋白结合肽（CREKA）向血栓靶向给药：一项硅学研究。
IF 3
Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-04-30 DOI: 10.4155/tde-2023-0107
Mohammad Soroosh Hajizade, Mohammad Javad Raee, Seyed Nooreddin Faraji, Fakhrossadat Farvadi, Maryam Kabiri, Sedigheh Eskandari, Ali Mohammad Tamaddon
{"title":"Targeted drug delivery to the thrombus by fusing streptokinase with a fibrin-binding peptide (CREKA): an <i>in silico</i> study.","authors":"Mohammad Soroosh Hajizade, Mohammad Javad Raee, Seyed Nooreddin Faraji, Fakhrossadat Farvadi, Maryam Kabiri, Sedigheh Eskandari, Ali Mohammad Tamaddon","doi":"10.4155/tde-2023-0107","DOIUrl":"10.4155/tde-2023-0107","url":null,"abstract":"<p><p><b>Aim:</b> Streptokinase has poor selectivity and provokes the immune response. In this study, we used <i>in silico</i> studies to design a fusion protein to achieve targeted delivery to the thrombus. <b>Materials & methods:</b> Streptokinase was analyzed computationally for mapping. The fusion protein modeling and quality assessment were carried out on several servers. The enzymatic activity and the stability of the fusion protein and its complex with plasminogen were assessed through molecular docking analysis and molecular dynamics simulation respectively. <b>Results:</b> Physicochemical properties analysis, protein quality assessments, protein-protein docking and molecular dynamics simulations predicted that the designed fusion protein is functionally active. <b>Conclusion:</b> Our results showed that this fusion protein might be a prospective candidate as a novel thrombolytic agent with better selectivity.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"399-411"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of fexofenadine self-microemulsifying delivery systems: an efficient way to improve intestinal permeability. 开发非索非那定自微乳化给药系统：改善肠道渗透性的有效方法。
IF 3
Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-06-28 DOI: 10.1080/20415990.2024.2363635
Ziba Islambulchilar, Ashkan Barfar, Shahla Mirzaeei
{"title":"Development of fexofenadine self-microemulsifying delivery systems: an efficient way to improve intestinal permeability.","authors":"Ziba Islambulchilar, Ashkan Barfar, Shahla Mirzaeei","doi":"10.1080/20415990.2024.2363635","DOIUrl":"10.1080/20415990.2024.2363635","url":null,"abstract":"<p><p><b>Aim:</b> The present study aimed to prepare and evaluate fexofenadine self-microemulsifying drug-delivery systems (SMEDDS) formulation and to determine and compare its intestinal permeability using <i>in situ</i> single-pass intestinal perfusion (SPIP) technique.<b>Methods:</b> Fexofenadine-loaded SMEDDS were prepared and optimized. Droplet size, polydispersity index, zeta potential, drug release and intestinal permeability were evaluated.<b>Results:</b> Optimized formulation consisted of 15% oil, 80% surfactant and 5% cosolvent. Droplet size and drug loading of optimized formulation was 13.77 nm and 60 mg/g and it has released 90% of its drug content. Intestinal permeability of fexofenadine was threefold enhanced in SMEDDS compared with free fexofenadine.<b>Conclusion:</b> The results of our study revealed that SMEDDS could be a promising tool for oral delivery of fexofenadine with enhanced dissolution rate and intestinal permeability.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"593-604"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11412145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
March Industry News. 三月行业新闻。
IF 3
Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-06-28 DOI: 10.1080/20415990.2024.2365621
Fiona McCartney
{"title":"March Industry News.","authors":"Fiona McCartney","doi":"10.1080/20415990.2024.2365621","DOIUrl":"10.1080/20415990.2024.2365621","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"561-566"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11412147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of EYP-1901 in neovascular age-related macular degeneration and diabetic eye diseases: review of Phase I/II trials. EYP-1901 在新生血管性老年黄斑变性和糖尿病眼病中的作用：I/II 期试验回顾。
IF 3
Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-10-03 DOI: 10.1080/20415990.2024.2406226
Abrahem Sayed, Pranesh Ravichandran, Cecilia Canizela, Rehan M Hussain
{"title":"Role of EYP-1901 in neovascular age-related macular degeneration and diabetic eye diseases: review of Phase I/II trials.","authors":"Abrahem Sayed, Pranesh Ravichandran, Cecilia Canizela, Rehan M Hussain","doi":"10.1080/20415990.2024.2406226","DOIUrl":"10.1080/20415990.2024.2406226","url":null,"abstract":"<p><p>EYP-1901 (Duravyu) has demonstrated promising outcomes in Phases I and II clinical trials for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)/diabetic retinopathy. This innovative treatment capitalizes on the potent anti-angiogenic properties of vorolanib, an inhibitor that targets all isoforms of VEGF, effectively mitigating the pathological neovascularization and vascular permeability that underpin these retinal conditions. EYP-1901 is integrated with the Durasert drug delivery system to administer a sustained release of vorolanib directly to the posterior segment of the eye. This delivery system ensures a consistent therapeutic effect over an extended period and significantly reduces the frequency of clinical interventions required, offering a more convenient treatment regimen while maintaining patient safety.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"829-843"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial peptide-fibrin glue mixture for treatment of methicillin-resistant Staphylococcus aureus-infected wounds. 用于治疗耐甲氧西林金黄色葡萄球菌感染伤口的抗菌肽-纤维蛋白胶混合物。
IF 3
Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-07-16 DOI: 10.1080/20415990.2024.2369497
Mehran Bahreini, Mehrdad Moosazadeh Moghaddam, Masoud Ghorbani, Mohammad Reza Nourani, Reza Mirnejad
{"title":"Antimicrobial peptide-fibrin glue mixture for treatment of methicillin-resistant <i>Staphylococcus aureus</i>-infected wounds.","authors":"Mehran Bahreini, Mehrdad Moosazadeh Moghaddam, Masoud Ghorbani, Mohammad Reza Nourani, Reza Mirnejad","doi":"10.1080/20415990.2024.2369497","DOIUrl":"10.1080/20415990.2024.2369497","url":null,"abstract":"<p><p><b>Aim:</b> This study was conducted to investigate the effect of fibrin glue-CM11 antibacterial peptide mixture (FG-P) on the healing of infected wounds <i>in vivo</i>.<b>Materials & methods:</b> We formulated a mixture of FG-P and evaluated its antimicrobial activity <i>in vitro</i> against multidrug-resistant (MDR) bacteria involved in wound infection as well as its healing effect on wound infected by methicillin-resistant <i>S. aureus</i> (MRSA) <i>in vivo</i>.<b>Results:</b> The peptide had an MIC of 8 μg/ml against all bacteria isolates. Growth inhibition zones were evident for FG-P compared with FG. The <i>in vivo</i> study showed that the FG-P could be significantly effective in healing the MRSA-infected wound.<b>Conclusion:</b> The use of FG-P mixture is a very suitable option for treating infected wounds.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"577-591"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11412140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of sphingolipid-based nanocarriers in drug delivery: an overview. 鞘脂类纳米载体在给药中的应用：综述。
IF 3
Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-07-29 DOI: 10.1080/20415990.2024.2377066
Samarth Kumar, Ajit Singh, Prachi Pandey, Ajay Khopade, Krutika K Sawant
{"title":"Application of sphingolipid-based nanocarriers in drug delivery: an overview.","authors":"Samarth Kumar, Ajit Singh, Prachi Pandey, Ajay Khopade, Krutika K Sawant","doi":"10.1080/20415990.2024.2377066","DOIUrl":"10.1080/20415990.2024.2377066","url":null,"abstract":"<p><p>Sphingolipids (SL) are well recognized for their cell signaling through extracellular and intracellular pathways. Based on chemistry different types of SL are biosynthesized in mammalian cells and have specific function in cellular activity. SL has an ampiphilic structure with have hydrophobic body attached to the polar head enables their use as a drug delivery agent in the form of nanocarriers. SL-based liposomes can improve the solubility of lipophilic drugs through host and drug complexes and are more stable than conventional liposomal formulations. Preclinical studies of SL nanocarriers are reported on topical delivery, oral delivery, ocular delivery, chemotherapeutic delivery, cardiovascular delivery and Alzheimer's disease. The commercial challenges and patents related to SL nanoformulations are highlighted in this article.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"619-637"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11412150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141789107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Industry Update: the latest developments in the field of therapeutic delivery, July 2024. 行业最新动态：2024 年 7 月治疗给药领域的最新发展。
IF 3
Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-10-18 DOI: 10.1080/20415990.2024.2414732
Peter Timmins
{"title":"Industry Update: the latest developments in the field of therapeutic delivery, July 2024.","authors":"Peter Timmins","doi":"10.1080/20415990.2024.2414732","DOIUrl":"https://doi.org/10.1080/20415990.2024.2414732","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"15 12","pages":"911-920"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信